Antibodies which bind human endothelin receptor a (ETAR)
AssigneeREMD Biotherapeutics, Inc.
InventorsHai Yan, John Zhang
Life of this patent
Estimating the term…
Abstract
This application provides isolated antibodies, and antigen-binding fragments thereof, that specifically bind endothelin A receptor (ETAR). These ETAR antibodies, or antigen-binding fragments thereof, have a high affinity for ETAR, function to effectively block ET-1 binding to ETAR, are less immunogenic compared to their unmodified parent antibodies in a given species (e.g., in a human), and can be used to treat ETAR-associated disorders. Importantly, compared to small molecule ETAR antagonists, the antibodies of the present invention have advantages of longer serum half-life, higher target specificity, thereby limiting the risk of off-target toxicity and improving therapeutic window.
Claims7
An isolated antibody or antigen-binding fragment thereof which comprises:
- (a) a light chain CDR1 sequence identical to SEQ ID NO:
- 13;
- (b) a light chain CDR2 sequence identical to SEQ ID NO:
- 15;
- (c) a light chain CDR3 sequence identical to SEQ ID NO:
- 18;
- (d) a heavy chain CDR1 sequence identical to SEQ ID NO:
- 4;
- (e) a heavy chain CDR2 sequence identical to SEQ ID NO:
- 7;
- and (f) a heavy chain CDR3 sequence identical to SEQ ID NO:
- 10.
An isolated humanized antibody or antigen-binding fragment thereof that specifically binds to human ETAR and is selected from the group consisting of an antibody which comprises the heavy chain sequence set forth in SEQ ID NO:
- 38, and the light chain sequence set forth in SEQ ID NO:
- 40, an antibody which comprises the heavy chain sequence set forth in SEQ ID NO:
- 42, and the light chain sequence set forth in SEQ ID NO:
- 40, and an antibody which comprises the heavy chain sequence set forth in SEQ ID NO:
- 44, and the light chain sequence set forth in SEQ ID NO:
- 40.
Dependencies are inferred from the claim text.